NEW YORK — Octave Bioscience said Tuesday that its Multiple Sclerosis Disease Activity (MSDA) test has received certification from the New York State Clinical Laboratory Evaluation Program.
The test measures the levels of 18 proteins in blood to provide a measure of disease activity in individuals with multiple sclerosis to guide treatment options. It was launched in late 2022 and is performed in Octave's CLIA-certified and College of American Pathology-accredited lab.
"The certification of Octave's MSDA Test in New York state … means the test now is certified across the US," Octave President and CEO Doug Biehn said in a statement.
In late 2023, Octave said that the test was already in use at several dozen multiple sclerosis clinics around the country. Earlier this year, the Menlo Park, California-based company announced the publication of data showing that it could impact clinical decision-making in real-world multiple sclerosis care.